The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-07. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
In the process, he found that a precipitation of thorium A (polonium-216) and thorium B (lead-212) also contained a short-lived "element", which he named thorium C (which was later identified as polonium-212). Hahn was unable to separate it, and concluded that it had a very short half-life (it is about 300 ns). He also identified radioactinium (thorium-227) and radium D (later identified as lead-210). Rutherford remarked that: "Hahn has a special nose for discovering new elements."
=== Weaning === During weaning, decreased prolactin, missing mechanical stimulation (baby suckling), and changes in osmotic balance caused by milk stasis and leaking of tight junctions cause cessation of milk production. It is the (passive) process of a child or animal ceasing to be dependent on the mother for nourishment. In some species there is complete or partial involution of alveolar structures after weaning, in humans there is only partial involution and the level of involution in humans appears to be highly individual. The glands in the breast do secrete fluid also in nonlactating women. In some other species (such as cows), all alveoli and secretory duct structures collapse by programmed cell death (apoptosis) and autophagy for lack of growth promoting factors either from the ECM or circulating hormones. At the same time, apoptosis of blood capillary endothelial cells speeds up the regression of lactation ductal beds. Shrinkage of the mammary duct tree and ECM remodeling by various proteinase is under the control of somatostatin and other growth inhibiting hormones and local factors. This major structural change leads loose fat tissue to fill the empty space afterward. But a functional lactiferous duct tree can be formed again when a female is pregnant again.
=== Media and arts representation of sickle cell disease === Popular media and art have been important educational tools about sickle cell disease. Hertz Nazaire was a Haitian-American visual artist, writer, and advocate who lived with sickle cell disease and used his art to raise awareness, combat stigma, and champion better access to care. Representations of sickle cell disease in television shows include in the longrunning American medical drama ER (season 4 "Obstruction of Justice" and season 15 "Separation Anxiety" and "Dream Runner"), the 2024 British superhero series Supacell, in the 2024 period drama Lady in the Lake, and in the 2025 medical procedural drama The Pitt (episode "8:00 am"). Noah Wyle, who plays Dr. Michael "Robby" Robinavitch on The Pitt, has spoken about the importance of popular media representation of sickle cell and the impacts of racism on the quality of care patients receive. Sickle cell disease has also been featured in several movies including the 1973 Sydney Poitier classic, A Warm December, 1996 Nigerian drama Mortal Inheritance, Genie Award- winning 2008 Canadian drama Nurse.Fighter.Boy, the 2017 animated documentary Spilled Milk, the 2020 Nigerian drama Strain, the 2022 animated short The Park Bench, and the 2023 American sci-fi action film Transformers: Rise of the Beasts.
Taurine is an amino sulfonic acid and not an amino carboxylic acid, however it is occasionally considered as such as the amounts required to suppress the auxotroph in certain organisms (such as cats) are closer to those of "essential amino acids" (amino acid auxotrophy) than of vitamins (cofactor auxotrophy). The osmolytes, sarcosine and glycine betaine are derived from amino acids, but have a secondary and quaternary amine respectively.
Sources: en.wikipedia.org
==== Bridges ==== Albany has both the Ellsworth Street Bridge which was constructed in 1926 and the Lyon Street Bridge that was constructed in 1973. They are both two-lane bridges that make up part of U.S. Route 20. The two bridges connect Linn to the south with Benton county in the north as they pass across the Willamette River. this makes up the major connection of downtown Albany with the north end of town and to Corvallis.
Claus von Bülow (born Claus Cecil Borberg; 11 August 1926 – 25 May 2019) was a British lawyer, consultant and socialite. In 1982, he was convicted of attempting to murder his wife Sunny von Bülow (born Martha Sharp Crawford; 1932–2008) in 1979, which had left her in a temporary coma, and in 1980, when an alleged insulin overdose left her in a persistent vegetative state for the rest of her life. On appeal, both convictions were reversed, and von Bülow was found not guilty at his second trial.
Continuously reduce bacterial contamination, achieving a 99.9% reduction within two hours of exposure; Kill greater than 99.9% of Gram-negative and Gram-positive bacteria within two hours of exposure; Deliver continuous and ongoing antibacterial action, remaining effective in killing greater than 99.9% of bacteria within two hours; Kill greater than 99.9% of bacteria within two hours, and continue to kill 99% of bacteria even after repeated contamination; Help inhibit the buildup and growth of bacteria within two hours of exposure between routine cleaning and sanitizing steps. See: Antimicrobial copper touch surfaces for the main article.
Due caution needs to be exercised – this includes appropriate personnel protective equipment (PPE) such as a flotation device, adequate training and working in pairs. To further optimize safety, equipment and accessories should include: two-way radios, amphibious vehicles, winch on wheeled vehicles. Ice thickness may be measured with ice augers, at required distance intervals or using a ground-penetrating radar (GPR). This is important, since an ice cover can vary as much as 70% in thickness over a few hundred meters, and the minimum ice thickness is used to determine the bearing capacity of the entire ice cover. Borehole drilling may be used to collect cores of the ice, so as to appreciate its internal structure, e.g. white ice versus clear ice. Snow cover removal is the first major operation in an ice road construction scheme. It may only begin once the ice thickness is safe to support the machinery used for that operation. There are two ways of doing it, depending on available equipment and state of practice for that particular road. One is to pack the snow layer with tracked vehicles into a thin layer, thereby increasing its density and reducing its insulating properties. The other is to remove it altogether, typically with vehicles fitted with a snowplow. Once the ice has reached the target thickness (via accelerated growth after removing the insulating effects of the snow), road construction per se may commence.
== Function == As its name suggests, NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons) and is critical for the survival and maintenance of sympathetic and sensory neurons as they undergo apoptosis in its absence. However, several recent studies suggest that NGF is also involved in pathways besides those regulating the life cycle of neurons.
Sources: en.wikipedia.org
Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. Even for diseases of unknown cause, molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. Many of these molecules, which are mainly cytokines, are directly involved in the immune system. Biological therapy has found a niche in the management of cancer, autoimmune diseases, and diseases of unknown cause that result in symptoms due to immune related mechanisms. Inflammatory bowel disease (IBD), a collection of systemic diseases involving inflammation of the gastrointestinal tract, includes two (or three) diseases of unknown causation: ulcerative colitis, which affects only the large bowel; Crohn's disease, which can affect the entire gastrointestinal tract; and indeterminate colitis, which consists of large bowel inflammation that shows elements of both Crohn's disease and ulcerative colitis. Although the causes of these diseases are unknown, genetic, environmental, immune, and other mechanisms have been proposed. Of these, the immune system plays a large role in the development of symptoms. Given this, a variety of biological therapies (such as TNF inhibitors and interleukin antagonists) have been developed for the treatment of these diseases.
Suppression of transthyretin production: Until 2018, liver and/or heart transplantation were the only ways to definitively treat TTR amyloidosis. Liver transplantation replaces the liver that is producing abnormal TTR proteins, and a heart transplantation replaces the heart with amyloid deposits for a non-diseased heart. Liver transplantation does not always halt the disease, and in some cases disease progression continues. Medications such as patisiran and inotersen can also decreases the activity of the transthyretin genes. These medications bind to the mRNA of transthyretin and prevent the production of the transthyretin protein, thus decreasing the overall amount of transthyretin that can accumulate in the body. Stabilization of abnormal transthyretin: There are medications that can stabilize the normally folded transthyretin, preventing misfolding and subsequent amyloid deposition. These medications include tafamidis, the non-steroidal anti-inflammatory drug (NSAID) diflunisal, and acoramidis. Tafamidis is a medication that binds to transthyretin and keeps it in its normal shape, stopping it from aggregating into amyloid fibrils. Diflunisal and acoramidis work in a similar manner to tafamidis in their ability to bind to and stabilize transthyretin. In a 30-month trial, tafamidis showed reduced mortality and reduced heart failure related hospitalizations compared to placebo. Tafamidis was also shown to improve functional capacity and quality of life in those with TTR amyloidosis.
3-Hydroxyeticyclidine (3-HO-PCE) is a novel dissociative drug of the arylcyclohexylamine class, related to phencyclidine. It was first identified as a novel psychoactive substance in Sweden in 2017, and has subsequently been sold online as a research chemical. The toxicity and long-term safety profile of 3-HO-PCE is unknown as it has a very limited history of use, although one study indicates moderate potential toxicity.
=== Propagation === Seeds of A. chilensis germinate without cold stratification. In zones with the possibility of frost, it is recommended to sow in spring in a greenhouse. If they have grown enough, by autumn, the new plants can be planted into individual pots. The potted plants should stay in the greenhouse for the first winter. The following year, after the last expected frost in spring, the plants can be planted out into their final positions. In their first winter outdoors, some type of frost protection is required. For further propagation, vegetative propagation is possible: cuttings of wood with a length of 15 to 30 centimetres (5.9 to 11.8 in) can be planted into pots. These cuttings normally root, and can be planted out in the following spring.
Mala is a numbing and pungent seasoning derived from Sichuan peppercorn and chili. Most commonly, mala is made into a sauce (麻辣醬 málàjiàng) by simmering it in oil and other spices. Characteristic of Sichuan cuisine, particularly Chongqing cuisine, it has become one of the most popular and synthesized ingredients in Chinese cuisine.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.